HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Hematological Malignancy Clinical Trial

Official title:

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Following Fludarbine/Melphalan/Total Body Irradiation Conditioning Regimen

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03850366
• Other study ID #: 10313
• Status: Recruiting
• Phase: Phase 2
• Start date: March 8, 2016
• Est. completion date: January 1, 2026

Study information

• Verified date: January 2024
• Source: Henry Ford Health System
• Contact: shatha farhan
• Phone: 313 713 3910
• Email: sfarhan1[@]hfhs.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can prevent GVHD and help enhance immune reconstitution. this study is to assess the engraftment rate in patients with hematologic malignancies who need allogeneic stem cell transplant but do not have a suitable matched related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and bortezomib

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: January 1, 2026
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 18-65 years old patient lacking a matched related donor or unrelated donor but have a related haploidentical donor (</= 7/8 allele match at the A, B, C, DR loci with a minimum match of 5/10 is required) is identified

• Candidate for stem cell transplant in a malignant hematological condition

• Karnofsky Performance Scale 0-1

• Available donor able to undergo a Peripheral blood stem cells collection

• Bilirubin </= 1.5 mg/dl , aspartate aminotransferase (AST) or alanine aminotransferase (ALT) </= 200 IU/ml for adults.

• Serum creatinine clearance >/=60 ml/min (calculated with Cockroft-Gault formula)

• Diffusing capacity for carbon monoxide (DLCO) >/= 45% predicted corrected for hemoglobin.

• Left ventricle ejection fraction > 40%.

• Patient or patient's legal representative, parent(s) or guardian should provide written informed consent.

Exclusion Criteria:

• Adult who has a suitable related or unrelated donor or cord units available for transplant. Suitable donors include 8/8 (HLA-A,B,C and DR, with all loci high-resolution typing) or 7/8 related or unrelated donor available within 42 days of search initiation

• HIV positive; active hepatitis B or C

• Patients with active uncontrolled infections.

• Liver cirrhosis

• Uncontrolled central nervous system involvement by tumor cells

• Positive Beta Human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.

• Inability to comply with medical therapy or follow-up

Related Conditions & MeSH terms

• Hematologic Neoplasms
• Hematological Malignancy

Intervention

Drug:
• Bortezomib
GVHD prophylaxis

Locations

Country	Name	City	State
United States	Henry Ford hospital	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	engraftment rate	rate of neutrophil and platelet engraftment post stem cell transplant	within 30 days post transplant